Table 3.

Competing risk regression to evaluate the effect of selected covariates on prostate cancer incidence

	Full-time follow-up period, n = 1997				Restricted to more than 20 year of follow-up, n = 1520
	Univariate analyses		Multivariate analysis		Multivariate analysis
	SHR (95 % CI)	P-value	SHR (95 % CI)	P-value	SHR (95 % CI)	P-value
Cholesterol (mmol/l)		<0.001*		<0.001*		0.01*
Q1 (2.7 – 5.8)	2.15 (1.44–3.22)	<0.001	2.00 (1.32–3.03)	0.001	2.00 (1.20–3.34)	<0.01
(5.9 – 6.6)	1.36 (0.88–2.09)	0.17	1.29 (0.83–2.00)	0.26	1.46 (0.86–2.48)	0.16
Q3 (6.7 – 7.4)	1.42 (0.92–2.21)	0.12	1.36 (0.87–2.12)	0.17	1.55 (0.90–2.66)	0.11
Q4 (7.5 – 15.4)	1		1		1
Age at inclusion (years)		0.48*		0.40*		0.36*
< 45	1		1		1
45–49	0.84 (0.58–1.20)	0.33	0.92 (0.64–1.32)	0.66	0.97 (0.66–1.43)	0.89
50–54	0.87 (0.60–1.25)	0.45	1.09 (0.73–1.62)	0.67	0.86 (0.54–1.35)	0.51
55+	0.85 (0.57–1.27)	0.43	1.15 (0.75–1.79)	0.52	0.80 (0.46–1.40)	0.44
Smoking
Never	1		1		1
Ever	0.75 (0.56–1.01)	0.06	0.79 (0.59–1.07)	0.12	0.81 (0.58–1.14)	0.22
Physical fitness (kJ/kg)		<0.001*		0.01*		0.12*
T1 (21.1 – 118.6)	1		1		1
T2 (118.7 – 161.2)	1.38 (0.96–1.98)	0.08	1.43 (0.98–2.07)	0.06	1.27 (0.82–1.99)	0.29
T3 (161.3 – 515.9)	1.76 (1.25–2.48)	<0.01	1.68 (1.14–2.47)	0.01	1.43 (0.92–2.22)	0.11
Body mass index (kg/m2)
<25	1		1		1
≥ 25	0.66 (0.49–0.89)	<0.01	0.69 (0.52–0.93)	0.01	0.62 (0.44–0.88)	<0.01
Systolic blood pressure (mmHg)		0.59*		0.55*		0.41*
Q1 (88 – 118)	1		1		1
Q2 (120 – 128)	0.85 (0.59–1.23)	0.39	0.89 (0.62–1.28)	0.53	1.00 (0.66–1.51)	0.99
Q3 (130 – 140)	0.83 (0.57–1.22)	0.35	0.96 (0.65–1.40)	0.83	1.06 (0.68–1.65)	0.79
Q4 (142 – 220)	0.92 (0.64–1.32)	0.63	1.13 (0.78–1.65)	0.52	1.22 (0.78–1.93)	0.37

SHR sub-distribution hazard ratios, CI confidence interval, Q1 - Q4 quartiles, T1 - T3 tertiles

*P-value from test for trend across ordered categories